scan0109 - mistnews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137...

5

Upload: others

Post on 01-Mar-2021

2 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office

Page 2: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office

Page 3: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office

Page 4: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office

Page 5: scan0109 - MistNews · 2021. 1. 6. · ibnsinapharma 30 01000852771 44891137 Mohamed.shawky@ibnsinapharma.com 15/12 3/2 Mohamed.shawky@ibnsina-pharma.com : 0/0 5 Il Head Office

LEO80185-G23 Clinical Study Report 11-Oct-2011leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial... · 11.4.1.1 Primary Endpoint – Controlled Disease According to

CLINICAL STUDY REPORT - leo-pharma.comleo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical trial...clinical study report investigation on the acceptability of calcipotriol solution

PLATFORM - medtech-pharma.com€¦ · EU IVDR - Effect on companion diagnostic development Claudia Dollins, Merck ... Chair: Thomas Kühler, Sanofi Internet-of-Things (IoT) & connectivity

Significant progress - Heidelberg Pharma GmbHheidelberg-pharma.com/pdf/Berichte/20100223_WILEX_GB_2009_E.pdf · Cash flow statement Cash flow from operating activities (18,638) (22,830)

Effects of IL-21, KIR Blockade, and CD137 Agonism on the ...innate-pharma.com/sites/default/files/ash2014_preclinical_poster... · ———Through direct activation and engagement

Ibnsina Pharma Releases Audited FY18 Resultsresources.inktankir.com/isph/ISP-ER-4Q18.pdfand second-largest pharmaceutical distributor, released today its audited results for the fiscal

Financial Statements-Consolidated - beximco-pharma.combeximco-pharma.com/investor/audited-annual... · Beximco Pharmaceuticals Limited and its Subsidiaries Report on the Audit of

Dosage form factors influencing bioavailability Lec:5suli-pharma.com/uploads/lectures/5_Biopharmaceutics.pdf5.Composition and properties of capsule shell (including enteric capsules)

Sales Force Effectiveness - Channel Optimizationchannel-optimization-pharma.com/wp-content/uploads/sites/214/2017/...Sales Force Effectiveness ... ZS Associates Access Monitor™ 2015

Acquisition of Sepracor Inc. - ds-pharma.com

Interim Financial Statements (Un-audited) - Beximco ...beximco-pharma.com/investor/half-yearly-report-2019-2020.pdfBeximco Pharmaceuticals Limited and its Subsidiaries Consolidated

OIC-VET IbnSina Health Capacity Building Programme ... and Tobacco.pdf · OIC-VET IbnSina Health Capacity Building Programme (IbnSina-HCaB) S ES RIC STATISTICAL ECONOMIC AND SOCIAL

R&D Meeting - ds-pharma.com

Ibnsina Pharma Releases Audited 1H18 Resultsenterprise.press/wp-content/uploads/2018/08/ISP-ER-1H2018-Final.pdf · efficiency have given Ibn Sina control of 19.9% market share in

Strategic growth - heidelberg-pharma.comheidelberg-pharma.com/...WILEX_AnnualReport_2010_E.pdf · ANNUAL REPORT 2010 Strategic growth by complementing the value chain. Key gurﬁ

Peptic ulcer disease - suli-pharma.com ulcer disease 2017.pdf · ! 1! Peptic’ulcer’disease ’! DrKawaAhmad! PhDPharmaceutics!! 1! GIT ! Foodtakenintothemouthismixedwithsalivatoformaplasticmass.Thesalivaryglands

Netnography: A Useful Market Research Tool for ...consulting-for-pharma.com/.../pharma_netnography_cfp_part2.pdf · Does netnography support the success of my medicinal product? 4

Peptic ulcer disease - suli-pharma.com

Dr. Mohammed N. Sabir 2021 - suli-pharma.com

ATACs fighting Cancer - heidelberg-pharma.com · ATACs fighting Cancer March 21, 2019 FY 2018 Financial Results & Business Update

DRAFT RED HERRING PROSPECTUS March 24 ... - calyx-pharma…calyx-pharma.com/new/Calyx_DRHP.pdf · CALYX CHEMICALS AND PHARMACEUTICALS LIMITED ... Golavli, Kalyan Shil Road, Dombivli

9-MONTH FINANCIAL REPORT 2015heidelberg-pharma.com/pdf/Berichte/20151015_WLX_QB_03_2015_e.pdfAfter reporting a very successful first half from a scientific and financial perspective,

COMPANY PROFILE EXCELLENT - Pharmaexcellent-pharma.com/wp-content/uploads/2016/11/Company-Profile.pdfleading companies through various agreements, partnerships and joint ventures,

calyx-pharma.comcalyx-pharma.com/Annexure 1_Calyx Chemicals and Pharmaceuticals... · Process for Corporate Person) Regulations, 2016, ... Security for WCL - LC/ LCBD/ LOC First hypothecation

Ibnsina Pharma Releases Audited 9M18 Results · Mohamed Shawky Investor Relations Manager Email: [email protected] Shareholding Structure (Post IPO and Capital Increase)

Investor Webinar - investor.xenon-pharma.com

Ibnsina Pharma Releases 9M2019 Results...2 | Ibnsina Pharma 9M2019 EARNINGS RELEASE Cairo | 4 November 2019 Comments from our Co-CEOs “We are pleased with Ibnsina’s performance

ISP ER 1Q19 - E - Final · Established in 2001, Ibnsina Pharma “ISP” is the fastest growing, and 2nd largest, pharmaceutical distributor in Egypt with a market share of 19.7%

5 solutions pour défendre l ... - smart-pharma.com€¦ · Confidentiel Smart Pharma Consulting Introduction Les politiques successives visant à maîtriser l’évolution des dépenses

Investor Presentation · …with a proven track record of success… Market Share 7.0% Established in 2001 under the name “Ibnsina Laborex” in partnership with Pinault Printemps

Regulatory Affairs - Startseite | GBA Labor · GBA-PHARMA.COM Your Challenges Require Smart Solutions. GBA PHARMA GmbH . Fraunhoferstrasse 11 a, 82152 Martinsried, Germany. Regulatory

3-MONTH FINANCIAL REPORT 2009heidelberg-pharma.com/pdf/Berichte/090408_WILEX_QB_01_2009_e.pdf · The planned milestone payments secure the Company’s finan-cing until the first quarter

PROGRAM AT A GLANCE 7TH INTERNATIONAL CONGRESS OF …bnpl.org.in/images/PROGRAM_20-01-2020.pdf · CRIUM, Hyderabad, INDIA Topic: Emerging trends in the management of Vitiligo IbnSina

Physicochemical Properties of Drugs Affecting Bioavailabilitysuli-pharma.com/uploads/lectures/4_Biopharmaceutics.pdf · 2019-11-29 · •Drug Factors affecting dissolution rate •Factors

TIM GASTROINTESTINAL TESTING - TNO Japan …tno-pharma.com/TIM_2017.pdfTIM GASTROINTESTINAL TESTING Triskelion tests and analyses chemical, pharmaceutical and biotechnology products,